P
Priscilla de Aquino Martins
Publications - 7
Citations - 1600
Priscilla de Aquino Martins is an academic researcher. The author has contributed to research in topics: Rivaroxaban & Population. The author has an hindex of 5, co-authored 6 publications receiving 786 citations.
Papers
More filters
Journal ArticleDOI
Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome A Randomized Clinical Trial
Alexandre Biasi Cavalcanti,Erica Aranha Suzumura,Lígia Nasi Laranjeira,Denise M. Paisani,Lucas P. Damiani,Hélio Penna Guimarães,Edson Romano,Marisa de Moraes Regenga,Luzia Noriko Takahashi Taniguchi,Cassiano Teixeira,Roselaine Pinheiro de Oliveira,Flávia Ribeiro Machado,Fredi Alexander Diaz-Quijano,Meton Soares de Alencar Filho,Israel Silva Maia,Eliana Bernardete Caser,Wilson de Oliveira Filho,Marcos C. Borges,Priscilla de Aquino Martins,Mirna Matsui,Gustavo A. Ospina-Tascón,Thiago Simões Giancursi,Nelson Dario Giraldo-Ramirez,Silvia Regina Rios Vieira,Maria da Graça Pasquotto de Lima Assef,Mohd Shahnaz Hasan,Wojciech Szczeklik,Fernando Rios,Marcelo B. P. Amato,Otavio Berwanger,Carlos Roberto Ribeiro de Carvalho +30 more
TL;DR: In patients with moderate to severe ARDS, a strategy with lung recruitment and titrated PEEP compared with low PEEP increased 28-day all-cause mortality, and these findings do not support the routine use of lung recruitment maneuver and PEEP titration in these patients.
Journal ArticleDOI
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Renato D. Lopes,Pedro Gabriel Melo de Barros e Silva,Remo H.M. Furtado,Ariane Vieira Scarlatelli Macedo,Bruna Bronhara,Lucas P. Damiani,Lilian Mazza Barbosa,Júlia de Aveiro Morata,Eduardo Ramacciotti,Priscilla de Aquino Martins,Aryadne Lyrio de Oliveira,Vinicius Santana Nunes,Luiz Eduardo Fonteles Ritt,Ana Thereza Rocha,Lucas Tramujas,Sueli V Santos,Dario Rafael Abregu Diaz,Lorena Souza Viana,Livia Maria Garcia Melro,Mariana Silveira de Alcântara Chaud,Estêvão Lanna Figueiredo,Fernando Carvalho Neuenschwander,Marianna Deway Andrade Dracoulakis,Rodolfo Godinho Souza Dourado Lima,Vicente C.S. Dantas,Anne Cristine Silva Fernandes,Otavio Gebara,Mauro E. Hernandes,Diego Aparecido Rios Queiroz,Viviane C Veiga,Manoel Fernandes Canesin,Leonardo Meira de Faria,Gilson Soares Feitosa-Filho,Marcelo Basso Gazzana,Idelzuíta Leandro Liporace,Aline de Oliveira Twardowsky,Lilia Nigro Maia,Flávia Ribeiro Machado,Alexandre de Matos Soeiro,Germano Emílio Conceição-Souza,Luciana Armaganijan,Patrícia O. Guimarães,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,John H. Alexander,Alvaro Avezum,Alexandre Biasi Cavalcanti,Otavio Berwanger +47 more
TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed
Journal ArticleDOI
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
Patrícia O. Guimarães,Daniel Quirk,Remo H. Furtado,Lilia N. Maia,José F. Saraiva,Murillo Oliveira Antunes,Roberto Kalil Filho,Vagner Madrini Junior,Alexandre de Matos Soeiro,Alexandre P. Tognon,Viviane C Veiga,Priscilla de Aquino Martins,Diogo D.F. Moia,Bruna S. Sampaio,Silvia R.L. Assis,Ronaldo V P Soares,Luciana P.A. Piano,Kleber Castilho,Roberta G.R.A.P. Momesso,Frederico Monfardini,Hélio Penna Guimarães,Dario Ponce de Leon,Majori Dulcine,Marcia Pinheiro,Levent M. Gunay,J. Jasper Deuring,Luiz Vicente Rizzo,Tamas Koncz,Otavio Berwanger +28 more
TL;DR: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo, and the proportional odds of having a worse score on the eight-level ordinal scale with tofacinib, as compared with placebo.
Journal ArticleDOI
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
Remo H.M. Furtado,Otávio Berwanger,Henrique Andrade Rodrigues da Fonseca,Thiago Domingos Corrêa,Leonardo José Rolim Ferraz,Maura G Lapa,Fernando G. Zampieri,Viviane C Veiga,Luciano Cesar Pontes Azevedo,Regis Goulart Rosa,Renato D. Lopes,Alvaro Avezum,Airton Leonardo de Oliveira Manoel,Felipe Maia de Toledo Piza,Priscilla de Aquino Martins,Thiago Lisboa,Adriano José Pereira,Guilherme B Olivato,Vicente C.S. Dantas,Eveline P. Milan,Otavio Gebara,Roberto Bleuel Amazonas,Monalisa Fernanda Bocchi de Oliveira,Ronaldo V P Soares,Diogo D.F. Moia,Luciana P.A. Piano,Kleber Castilho,Roberta G.R.A.P. Momesso,Guilherme Schettino,Luiz Vicente Rizzo,Ary Serpa Neto,Ary Serpa Neto,Flávia Ribeiro Machado,Alexandre Biasi Cavalcanti +33 more
TL;DR: The findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19 and suggest that standard of care treatment alone did not improve clinical outcomes.
Journal ArticleDOI
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
Renato D. Lopes,Pedro Gabriel Melo de Barros e Silva,Remo H.M. Furtado,Ariane Vieira Scarlatelli Macedo,Eduardo Ramacciotti,Lucas Petri Damini,Bruna Bronhara,Alexandre Biasi Cavalcanti,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,Viviane C Veiga,Flávia Ribeiro Machado,Luiz Eduardo Fonteles Ritt,Priscilla de Aquino Martins,John H. Alexander,Alvaro Avezum,Otavio Berwanger,Coalition Covid Brazil Iv Investigators +17 more
TL;DR: Action as discussed by the authors is an academic-led, pragmatic, multicenter, open-label, randomized, phase IV clinical trial that aims to enroll around 600 patients at 40 sites participating in the Coalition COVID-19 Brazil initiative.